These peptides differ in mechanism, evidence and regulatory status. Tesamorelin has a specific HIV-associated lipodystrophy indication; that approval does not extend to sermorelin, ipamorelin or general weight loss.
The regulatory history of Geref (sermorelin) does not make current compounded adult preparations approved products. FDA does not review compounded medicines for safety, effectiveness or quality before marketing. Source: FDA: Geref regulatory record Source: FDA: risks of compounded medicines
The short version
All three relate to the growth-hormone system, but they are distinct compounds that work differently:
- Sermorelin — a growth-hormone-releasing-hormone (GHRH) analog. It signals the pituitary gland through the GHRH receptor to release the body’s own growth hormone. The sermorelin prescribed today is a compounded medication, not an FDA-approved finished product. See the sermorelin treatment page.
- Ipamorelin — a growth-hormone secretagogue that acts through a different receptor pathway (the ghrelin / GH-secretagogue receptor) rather than the GHRH receptor.
- Tesamorelin — a distinct, more potent GHRH analog that carries its own FDA-approved indication in a specific clinical context.
Why the mechanism difference matters
Because sermorelin and ipamorelin act through different receptors, they are not simply stronger-or-weaker versions of the same thing — they are different tools. Tesamorelin, while in the GHRH-analog family like sermorelin, is a separate medication with its own approval and profile. None of these are interchangeable, and the differences are exactly why a clinical evaluation matters.
”Which is best?” is the wrong question
A lot of online content ranks these peptides as if one wins for everyone. That framing is misleading. Appropriateness depends on the individual — health history, goals, contraindications, and a provider’s clinical judgment. There is no universal best.
What about combining them?
You will sometimes see “sermorelin + ipamorelin” discussed as a stack. Combining prescription medications is a clinical decision only a licensed provider can make and is never something to self-direct. If a provider determines a particular approach is appropriate for you, they prescribe and supervise it.
The bottom line
Comparing peptides is useful for understanding, but the decision is clinical. If you are considering sermorelin specifically, the next step is an evaluation — not a comparison chart.
Want to know if sermorelin fits your situation? Start a clinical evaluation with REMEVi — a licensed US provider reviews your case before anything is prescribed. A four-week subscription with bilingual care.
Related reading: sermorelin benefits and sermorelin dosage.
This article is for general education and is not medical advice. Sermorelin is a non-FDA-approved compounded medication available only by prescription from a licensed provider after an individual evaluation.
Regulatory status and risks
Approved tesamorelin is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight loss. FDA identifies risks and insufficient safety information for compounded ipamorelin. Their mechanisms do not establish that combining them is safe. Source: FDA: compounding substances with potential safety risks Egrifta SV prescribing information
